Together, these findings suggest that while there are currently no reports of PI3K/Akt/mTOR pathway inhibitors being approved or tested in clinical trials for endometriosis, their efficacy in improving hormone resistance in oestrogen-dependent malignancies, their immunosuppressive properties, and their well-understood safety profiles from long-term use suggest that mTOR inhibitors may represent a safe therapeutic option for endometriosis. This evidence concerns the gene MTOR and endometriosis.